Joseph Driscoll - 14 Dec 2022 Form 4 Insider Report for Akoya Biosciences, Inc. (AKYA)

Role
Chief Financial Officer
Signature
/s/ Joseph Driscoll, by Brian McKelligon, as Attorney-in-Fact
Issuer symbol
AKYA
Transactions as of
14 Dec 2022
Net transactions value
-$297,877
Form type
4
Filing time
16 Dec 2022, 16:59:16 UTC
Previous filing
25 Mar 2022
Next filing
27 Dec 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AKYA Common Stock Options Exercise $4,417 +10,039 +80% $0.4400* 22,539 14 Dec 2022 Direct
transaction AKYA Common Stock Sale $127,187 -10,039 -45% $12.67 12,500 14 Dec 2022 Direct F1
transaction AKYA Common Stock Options Exercise $6,413 +14,574 +117% $0.4400* 27,074 14 Dec 2022 Direct
transaction AKYA Common Stock Sale $181,519 -14,574 -54% $12.46 12,500 14 Dec 2022 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AKYA Employee Stock Option (Right to Buy) Options Exercise $0 -10,039 -7.5% $0.000000 123,466 14 Dec 2022 Common Stock 10,039 $0.4400 Direct F3
transaction AKYA Employee Stock Option (Right to Buy Options Exercise $0 -14,574 -12% $0.000000 108,712 14 Dec 2022 Common Stock 14,574 $0.4400 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Column 4 reflects a weighted average price. Shares sold in multiple transactions at prices ranging from $12.60 - $12.80. Reporting person undertakes to provide issuer, securityholder of issuer or SEC staff, upon request, information regarding number of shares sold at each separate price within ranges set forth herein.
F2 Column 4 reflects a weighted average price. Shares sold in multiple transactions at prices ranging from $12.40 - $12.615. Reporting person undertakes to provide issuer, securityholder of issuer or SEC staff, upon request, information regarding number of shares sold at each separate price within ranges set forth herein.
F3 Such performance-based option shares were issued in 2019. In 2020, the options vested as performance conditions were determined to have been achieved.